On January 15, 2021 Taiho Pharmaceutical Co., Ltd. reported its establishment of a new headquarters, Taiho Oncology Europe GmbH in Zug, Switzerland, as a clinical development and commercial base for its pharmaceutical business in Europe (Press release, Taiho, JAN 15, 2021, View Source [SID1234574014]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Taiho Oncology Europe is established as a subsidiary of Taiho Pharmaceutical. Together with Taiho Pharmaceutical, Taiho Oncology, Inc. (Princeton, New Jersey), a subsidiary of Taiho Pharmaceutical, will support its operation in Europe.

Taiho Oncology Europe will be responsible for the European commercialization of futibatinib (development code; TAS-120), an FGFR inhibitor currently under development as a new oral anti-cancer agent, after obtaining marketing approval. Futibatinib is not yet approved in any country worldwide.

Taiho Pharmaceutical will further promote its globalization through Taiho Oncology Europe, and will strive to continue its contribution to cancer patients and caregivers worldwide.